Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12615000771550
ACTRN12615000771550
Not yet recruiting
Phase 2

Effect of Adaptive Radiotherapy on the dose to Organs at Risk and Target Volumes in patients with Locally Advanced Head and Neck Cancer

Susan Mincham0 sites20 target enrollmentJuly 24, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHead and Neck CancerCancer - Head and neck

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
Susan Mincham
Enrollment
20
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 24, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Susan Mincham

Eligibility Criteria

Inclusion Criteria

  • •Age 18 years or above
  • •\- Histologically proven squamous cell carcinoma of the head and neck region (oropharynx, nasopharynx, hypopharynx, larynx)
  • •\- Locally advanced disease (AJCC Stage III/IV)
  • •\- Multidisciplinary decision to treat with curative intent definitive radiation or chemoradiation using Image\-guided IMRT/VMAT
  • •\- ECOG 0\-2
  • •\- Able to give informed consent

Exclusion Criteria

  • •\- Definitive surgery to primary tumour or nodal disease
  • •\- Neoadjuvant chemotherapy
  • •\- Prior radiotherapy or chemotherapy
  • •\- Previous malignancy (except treated cutaneous skin cancers)
  • •\- Pregnant or breastfeeding women
  • •\- Both parotid glands entirely within the target volume (unable to achieve parotid sparing)
  • •\- Contraindications to radiotherapy (e.g. radiosensitivity syndromes)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
adaptive radiotherapy in prostate cancer patientsprostate cancer.Dysplasia of prostateN42.3
IRCT20181006041257N1Vice Chancellor for Research and Technology40
Recruiting
Not Applicable
Prospective validation of Adaptive Radiotherapy in patients with head and neck tumorsHead- and Neckregion, C00-C14, C40-44, C73-C97C00-C14C40-C41C43-C44C73-C75C76-C80C81-C96C97Malignant neoplasms of lip, oral cavity and pharynxMalignant neoplasms of bone and articular cartilageMelanoma and other malignant neoplasms of skinMalignant neoplasms of thyroid and other endocrine glandsMalignant neoplasms of ill-defined, secondary and unspecified sitesMalignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissueMalignant neoplasms of independent (primary) multiple sites
DRKS00033144Klinik für Strahlentherapie, Universitätsklinikum Essen, NCT West30
Recruiting
Not Applicable
The effect of different radiotherapy regimen on the immune cell landscapecancertumor10027656
NL-OMON52433Radboud Universitair Medisch Centrum200
Not yet recruiting
Not Applicable
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal cancerrectal carcinoma100179901001799110017998
NL-OMON51912niversitair Medisch Centrum Utrecht45
Recruiting
Not Applicable
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal cancer
NL-OMON22916MC Utrecht45